Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

ClinicalTrials.gov ID: NCT04603001

Public ClinicalTrials.gov record NCT04603001. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

Study identification

NCT ID: NCT04603001
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 260 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2020 (Actual)
Primary completion: Jul 3, 2023 (Actual)
Completion: May 2027 (Estimated)
Last update posted: Jul 22, 2026

2020 – 2027

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	—
UCLA Medical Center	Los Angeles	California	90095	—
University of California, Davis - Health Systems	Sacramento	California	95817	—
H Lee Moffitt Cancer Center	Tampa	Florida	33612-9497	—
Northwestern University	Chicago	Illinois	60611	—
University of Chicago Hospital	Chicago	Illinois	60637	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Roswell Park Cancer Institute	Buffalo	New York	14263-0002	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27514	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04603001, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 22, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04603001 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →